stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) Revenue
Roivant Sciences Ltd.'s revenue for fiscal 2026 was $8.3M, down 71.6% from $29.1M in fiscal 2025. Over the twelve months to 30 June 2026 it was $7.5M. Over the past ten years it has ranged from $8.3M (fiscal 2026) to $61.3M (fiscal 2023) — the current reading is the lowest in ten years. Revenue has fallen for 3 consecutive fiscal years. Roivant Sciences Ltd. ranks 223rd of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2026 | $8.3M | (71.57%) |
| FY2025 | $29.1M | (11.19%) |
| FY2024 | $32.7M | (46.62%) |
| FY2023 | $61.3M | 10.84% |
| FY2022 | $55.3M | 132.34% |
| FY2021 | $23.8M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $1.4M | (42.78%) |
| Mar 2026 | $2.5M | 26.06% |
| Dec 2025 | $2.0M | 27.24% |
| Sep 2025 | $1.6M | (27.60%) |
| 21 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $6.6B |
| INCY Incyte Corporation compare | $6.0B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $5.0B |
| GMAB Genmab A/S Sponsored ADR compare | $4.1B |
| BNTX BioNTech SE Sponsored ADR compare | $2.7B |
| RPRX Royalty Pharma PLC compare | $2.6B |
| INSM Insmed, Inc. compare | $1.5B |
| RVMD Revolution Medicines, Inc. compare | $209.1M |
| ROIV Roivant Sciences Ltd. | $7.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ROIV
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement